Novel [2′,5′-Bis-O-(tert-butyldimethylsily)-β-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-diozide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1158-1168

  De Castro, Sonia ^a   Lobatón, Esther ^a   Pérez Pérez, María Jesús ^a   San Félix, Ana ^a   Cordeiro, Alessandra ^a   Andrei, Graciela ^b   Snoeck, Robert ^b   De Clercq, Erik ^b   Balzarini, Jan ^b   Camarasa, María José ^a   Velázquez, Sonsoles ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3' SPIROAMINOOXATHIOLE DIOXIDE; [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE) DERIVATIVE; AMIDE; AMINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CARBONYL DERIVATIVE; ESTER; OXALIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPIRO COMPOUND; SULTONE; UNCLASSIFIED DRUG; UREA DERIVATIVE; DRUG DERIVATIVE; RNA DIRECTED DNA POLYMERASE; THYMIDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DESIGN; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; SYNTHESIS;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 20144369341     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040868q     Document Type: Article

References (30)

1. Jonckheere, H.; Anné, J.; De Clercq, E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 2000, 129-154.
2. Balzarini, J. Suppression of resistance to drugs targeted to human inmunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 1999, 58, 1-27.
3. Tavel, J. A.; Miller, K. D.; Masur, H. Guide to major clinical trials of antiretroviral therapy in human inmunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors. Clin. Infect. Dis. 1999, 28, 643-676.
4. (a) Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
5. (b) De Clercq, E. The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
6. (c) Drake, S. M.; NNRTIs-a new class of drugs for HIV. J. Antimicrob. Chemoth. 2000, 45, 615-657.
7. (a) Vella, S.; Palmisano, L. Antiretroviral therapy: state of the HAART. Antiviral Res. 2000, 45,1-7.
8. (b) Volberding, P. A. HIV therapy in 2003: consensus and controversy. AIDS 2003, 17, 4-11.
9. Delaugerre, C.; Rohban, R.; Simon, A.; Mouroux, M.; Tricot, C.; Agher, R.; Huraux, J. M.; Katlama, C.; Calvez, V. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol. 2001, 65 (3), 445-8.
10. (a) Balzarini, J.; Pérez-Pérez, M.-J.; San-Félix, A.; Schols, D.; Perno, C. F.; Vandamme, A.-M.; Camarasa, M.-J.; De Clercq, E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4392-4396.
11. (b) Camarasa, M.-J.; Pérez-Pérez, M.-J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″, 2″-oxathiole-2″,2″-dioxide]pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
12. Camarasa, M.-J.; San-Félix, A.; Pérez-Pérez, M.-J.; Vélazquez, S.; Alvarez, R.; Chamorro, C.; Jimeno, M. L.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J. HIV-1 specific reverse transcriptase inhibitors: why are TSAO-nucleosides so unique? J. Carbohydr. Chem. 2000, 19, 451-469.
13. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez- Pérez, M.-J.; Camarasa, M.-J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
14. Camarasa, M.-J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.-J.; Gago, F.; Balzarini, J. TSAO compounds; The comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 2004, 4, 945-963.
15. Balzarini, J.; Naesens, L.; Bohman, C.; Pérez-Pérez, M.-J.; San-Félix, A.; Camarasa, M.-J.; De Clercq, E. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-bis- O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]3-N-methyl-thymine] 3′-spiro-5″-(4″-amino1″,2″-oxathiole-2″, 2″-dioxide). Biochem. Pharmacol. 1993, 46, 69-77.
16. Harris, D.; Lee, R.; Misra, H. S.; Pandey, P. K.; Pandey, V. N. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998, 37, 5903-5908.
17. Sluis-Cremer, N.; Dmitrienko, G. I.; Balzarini, J.; Camarasa, M.-J.; Parniak, M. A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-{spiro-[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]]}-3-ethylthymine. Biochemistry 2000, 39, 1427-1433.
18. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A. J.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
19. (a) Balzarini, J.; Heim, J. P.; Riess, G.; Camarasa, M.-J.; De Clercq, E.; Karlsson, A. Sensitivity of (138 GLU → LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 1994, 201, 1305-1312.
20. 138 → Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
21. Lobatón, E.; Camarasa, M.-J.; Velázquez, S. An efficient synthesis of 3′-spiro sultone nucleosides functionalized on the sultone moiety via Pd-catalyzed cross-coupling reaction. Synlett 2000, 9, 1312-1314.
22. Lobatón, E.; Rodríguez-Barrios, F.; Gago, F.; Pérez-Pérez, M.-J.; De Clercq, E.; Balzarini, J.; Camarasa, M.-J.; Velázquez, S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 2001, 45, 3934-3945.
23. Pérez-Pérez, M.-J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M.-J. TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- β-D-ribofuranosyl]-3′-spiro-5″-(4′-amino-1′, 2′-oxathiole-2′,2′-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 1992, 35, 2988-2995.
24. Camarasa, M.-J.; Jimeno, M. L.; Pérez-Pérez, M.-J.; Alvarez, R.; Velázquez, S.; Lozano, A. Synthesis, NMR studies and theoretical calculations of novel 3-spiro-branched ribofuranoses. Tetrahedron 1999, 55, 12187-12200.
25. HOMO = -9.97 eV) according to HF/6-31G** FOpt studies.
26. Hurd, C. D.; Prapas, A. G. Preparation of acyclic imides. J. Chem. Soc. 1959, 24, 388-392.
27. Otera, J.; Dan-oh, N.; Nozaki, H. Novel template effects of distannoxane catalysts in highly efficient transesterification and esterification. J. Org. Chem. 1991, 56, 5307-5311.
28. Bonache, M. C.; Chamorro, C.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Velázquez, S.; Camarasa, M.-J.; San-Félix, A. Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors. Antiviral Chem. Chemother. 2003, 14, 249-262.
29. Gonzales, M. J.; Wu, T. D.; Taylor, J.; Belitskaya, I.; Kantor, R.; Israelski, D.; Chou, S.; Zolapa, A. R.; Fessel, W. J.; Shafer, R. W. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003, 17, 791-799.
30. Balzarini, J.; De Clercq, E.; Carbonez, A.; Burt, V.; Kleim, J. P. Long-term exposure of HIV-1 type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retroviruses 2000, 16, 517-528.